ReviewCancer2009
Thromboprophylaxis with low-molecular-weight heparin in medical patients with cancer.
Review in Cancer, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it, 36 citations in OpenAlex.
- Guidelines for treatment and prevention of venous thromboembolism among patients with cancer.Thrombosis research · 2014Pooled it
- Nationally representative estimates of health care burden of venous thromboembolism in hospitalized cancer patients.Research and practice in thrombosis and haemostasis · 2026Article
- Cancer-Associated Thrombosis (CAT); mechanisms and treatment options.Thrombosis journal · 2025Review
- Apixaban versus low molecular weight heparin in patients with cancer-associated venous thromboembolism: a systematic review and meta-analysis.Annals of medicine and surgery (2012) · 2024Review
- Anticoagulation in cancer-associated thromboembolism with thrombocytopenia: a prospective, multicenter cohort study.Blood advances · 2021Observational
- Antiproliferative Properties of Scandium Exopolysaccharide Complexes on Several Cancer Cell Lines.Marine drugs · 2021Article
- Marine Exopolysaccharide Complexed With Scandium Aimed as Theranostic Agents.Molecules (Basel, Switzerland) · 2021Article
- Cellular and Molecular Effects of High-Molecular-Weight Heparin on Matrix Metalloproteinase 9 Expression.International journal of molecular sciences · 2019Article
- Insights into venous thromboembolism prevention in hospitalized cancer patients: Lessons from a prospective study.PloS one · 2018Article
- Cyclophosphamide, epirubicin and fluorouracil chemotherapy-induced alteration of haemostasis markers in breast cancer patients.Molecular and clinical oncology · 2015Article
- Pulmonary Venous Obstruction in Cancer Patients.Journal of oncology · 2015Article
- Pattern of frequent but nontargeted pharmacologic thromboprophylaxis for hospitalized patients with cancer at academic medical centers: a prospective, cross-sectional, multicenter study.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2014Article
- Estimated glomerular filtration rate is an easy predictor of venous thromboembolism in cancer patients undergoing platinum-based chemotherapy.The oncologist · 2014Article
- Thromboembolic disease in cancer patients.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2013Review
- Early changes of a novel APC-dependent thrombin generation assay during chemotherapy independently predict venous thromboembolism in cancer patients--a pilot study.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2012Article
- Venous thromboembolism in the patient with cancer: focus on burden of disease and benefits of thromboprophylaxis.Cancer · 2011Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
Abstract
Venous thromboembolism (VTE) is a frequent complication of cancer and cancer treatment and is associated with multiple clinical consequences, including recurrent VTE, bleeding, and an increase in the risk of death. Although the risks associated with VTE have been well recognized in surgical cancer patients, there is also considerable and increasing risk in medical cancer patients. VTE risk factors in medical cancer patients include the type and stage of cancer, major comorbid illnesses, current hospitalization, active chemotherapy, hormone therapy, and antiangiogenic agents. Low-molecular-weight heparins (LMWHs) are recommended commonly for the prevention of VTE in hospitalized cancer patients and in higher risk ambulatory cancer patients because of their favorable risk-to-benefit profile. These agents have demonstrated effectiveness in both the primary and secondary prevention of VTE in medical cancer patients. Extended-duration anticoagulant therapy is often recommended to reduce the risk of VTE recurrence in patients with cancer. LMWHs are often used for long-term prophylaxis because of a reduced need for coagulation monitoring, few major bleeding episodes, and once-daily dosing. Despite clinical and practical benefits, a substantial proportion of medical cancer patients do not receive VTE prophylaxis. To improve the appropriate prevention and treatment of VTE in cancer patients, guidelines have been published recently by the American Society of Clinical Oncology and the National Comprehensive Cancer Network. Widespread dissemination and application of these guidelines are encouraged to improve the appropriate use of these agents and to improve clinical outcomes in medical cancer patients at risk for VTE and its complications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.